Of note , however , GALNT2 drug1 ( previously associated with high-density lipoprotein cholesterol levels in EA ) had multiple potentially novel PheWAS associations , with hypertension related phenotypes in AA and with serum calcium levels and drug2 phenotypes in EA . 
The majority of the potentially novel results were for single PheWAS phenotype-classes , for example , for CDKN2A/B drug1 ( previously associated with type 2 drug2 in EA ) a PheWAS association was identified for hemoglobin levels in AA . 
However , the effect of drug1 : C>G in INK4 locus in familial drug2 patients and on lipid profile of the patients has not been studied in Pakistan . 
An epistatic interaction between drug1 and drug2 ( OR 1.56 , p=1.19 * 10 ( -2 ) ) was found especially in presence of drug3 disease ( OR=2.15 , p=3.12 * 10 ( -4 ) ) . 
In a longitudinal study with 11 years of follow-up on survival in the oldest-old Danes , only one SNP , drug1 ( IL6 ) , was borderline significantly associated with drug2 from age 92 ( P-corrected=0.064 ) . 
Haplotypes of drug1 and drug2 or drug3 and drug4 revealed an association with drug5 cancer which was significantly stronger in the homozygous carriers . 
The nonsynonymous OPRM1 drug1 might be a risk factor for drug2 to opioids or heroin in an Asian population . 
No association was found between drug2 phenotypes ( incidence , intensity , and duration ) and different drug1 genotypes . 
Results revealed an association between drug1 and cocaine and heroin drug2 in European Americans ( p=0.02 ; 95 % C.I. 0.47 [0.24-0.92 ] ) 
The 118G allele conferred 5.3-fold increased odds of drug2 / drug3 ( p<0.05 ) , while the drug1 variant allele was not associated with drug4 / drug5 
In this meta analysis , we assessed 10 case-control studies included 7,067 cases and 9,374 controls of the association between CYP1B1 SNPs of Leu432Val ( drug1 , 432C>G ) , Asn453Ser ( drug2 , 453A>G ) , Ala119Ser ( drug3 , 119G>T ) , Arg48Gly ( drug4 , 48C>G ) and the risk of drug5 . 
RESULTS : In our human study , the A118G singlenucleotide polymorphism drug1 was associated with drug2 virus disease severity ( p = 0.015 ) . 
Compared to controls , drug3 patients ( with and without drug4 ) showed significantly increased frequency of the DBH ( drug1 : OR 1.73 ; CI 1.15-2.59 ; P=0.008 ) and the OPRM1 risk genotypes ( drug2 : OR 1.71 ; CI 1.17-2.50 ; P=0.006 ) . 
In the present study we investigated whether the drug1 SNP could predict clinical outcome regarding progression of drug2 and disability in patients with low drug3 and drug4 after drug5 herniation . 
Earlier studies have shown that the single nucleotide polymorphism drug1 in the opioid receptor mu 1 ( OPRM1 ) gene may affect drug2 . 
Individuals were genotyped for PCSK9 R46L ( drug1 ) , ABCG8 D19H ( drug2 ) , and APOE R112C ( drug3 ) and R158C drug4 polymorphisms , all of which are associated with drug5 
Male children of alcoholics were less likely to be carriers of the G allele in single nucleotide polymorphism A118G ( drug1 ) , and those who were homozygous for the A allele were more likely to affiliate with alcohol use promoting peers who increased the risk for drug2 symptoms at all ages . 
The COMT drug1 gene polymorphism has been investigated as a susceptibility factor for drug2 . 
No statistically significant results were found in meta-analysis but one study reported that the drug1 allele was associated with drug2 . 
The COMT drug1 polymorphism was also found to modulate drug2 in normal people and drug3 . 
Whites with allele G of the functional polymorphism 118A > G ( reference sequence drug1 ) showed a smaller decrease in drug2 ; those bearing minor alleles IVS1 + 1050A , IVS1 + 14123A , and IVS2 + 31A showed a larger decrease in drug3 over interval X ( 0.01 < P < .05 ) 
Conflicting results were reported on the role of the mu-opioid receptor ( OPRM1 ) polymorphism A118G ( Asn40Asp , drug1 ) in the development of drug2 . 
drug3 were more sensitive to experimental pain than healthy volunteers and , in particular , drug4 individuals with the met/met genotype ( drug1 SNP ) or the HPS-APS haplotypes showing higher drug5 stimuli than patients carrying the LPS haplotype or val alleles ( drug2 NP ) . 
According with previous research , our findings revealed that haplotypes of the COMT geneand genotypes of the drug1 polymorphism play a key role on pain sensitivity in drug2 . 
we assessed 10 case-control studies included 7,067 cases and 9,374 controls of the association between CYP1B1 SNPs of Leu432Val drug1 Asn453Ser drug2 , Ala119Ser drug3 , drug4 nd the risk of drug5 . 
Our results suggest that there is no direct effect of drug1 genotype on the risk for drug2 among active heroin users . 
This study aimed to investigate associations between subjective response to drug2 and genetic polymorphisms and haplotypes in the u-opioid receptor including the exonic variant drug1 ( Asp40Asn ) . 
The study was focused on the relationship between the functional A118G polymorphism of the OPRM1 gene ( drug1 ) and drug2 in groups of 130 male patients and 452 male controls . 
The results of the present study reveal that the drug1 gene polymorphism is associated with a better glucose tolerance and improved IS , both of which suggest a potential protective effect of this variant on drug2 risk . . 
Moreover , we found that the drug1 allele was a dose-response protective factor for drug2 and the epsilon3 allele exerted a weaker dose-response protective effect for risk of AD compared with epsilon2 . 
drug1 was not significantly associated with drug2 in our sample . 
OBJECTIVE : Previous studies have investigated the role of drug1 ( CTLA-4 ) and drug2 factor-alpha ( TNF-a ) in carcinogenesis of osteosarcoma , but their results were inconsistent . 
Pooled results showed that drug1 polymorphism of CTLA-4 was associated with drug2 ( 
No significant associations were found between drug1 polymorphism of CTLA-4 or drug2 polymorphism of TNF-a and drug3 risk . 
The COMT drug1 genotype was associated with higher drug2 on the BIS-11 second-order factor Non-planning . 
In the total population , inheritance of the IL1R2 drug1 AA , drug2 AA , TNF drug3 GA + AA , and TNF rs673 GA genotypesmodestly increased drug4 risk by 1.45 to 11.7-fold relative to the referent genotype . 
Among U.S. men , age-adjusted dominant , recessive and additive genetic models for the IL1R2 drug1 locus were linked to an increase in drug2 susceptibility . 
As for drug1 polymorphism , the heterogeneous genotype showed a decreased risk for drug2 compared with the common homogenous genotype in a fixed-effect model in Asian population ( Met/Val vs . 
In order to study specific features of remitting multiple sclerosis patients with different genotypes of polymorphic loci rs1800629 gene TNFa , drug1 gene CD40 , drug2 gene KIF1B , drug3 IL-18 gene , conducted clinical and electrophysiological examination of 149 patients with drug4 . 
We have determined 4 frequent nonsynonymous gene polymorphisms of CYP1B1 in the human drug5 cell lines panels of the National Cancer Institut e ( NCI ) and the Japanese Foundation for Cancer Research ( JFCR ) : drug1 ( R48G ) , drug2 ( A119S ) , drug3 ( L432V ) , and drug4 ( N453S ) . 
BACKGROUND : Evidence has suggested that tumour necrosis factor ( TNF ) -a may be involved in the aetiology of drug3 , but the underlying association of the TNF-a polymorphisms -238G/A ( drug1 ) and -308G/A ( drug2 ) with the risk of drug4 is still unconfirmed . 
Evidence has suggested that tumour necrosis factor ( TNF ) -a may be involved in the aetiology of psoriasis , but the underlying association of the TNF-a polymorphisms -238G/A drug1 and -308G/A drug2 with the risk of drug3 is still <ModMar>unconfirmed<ModMar> 
CONCLUSIONS : We have confirmed associations between drug3 and drug1 and drug2 . 
Objective : We have conducted the first study of the association of interleukin ( IL ) -10 , tumor necrosis factor alpha ( TNF-a ) , and drug1 region single nucleotide polymorphisms ( SNPs ) with drug2 in Western Algeria . 
Our results show a potential influence of the drug1 deletion on the risk of drug2 disease among patients with drug3 . 
There was no association of drug1 with drug2 in the combined sample ( n=4071 , p=0.110 , odds ratio=1.08 ) . 
Our results do not support the association of drug1 with drug2 in the Han Chinese population . 
BACKGROUND : Genotypes of tumor necrosis factor alpha ( TNF-a ) and its surface receptors , drug1 and drug2 , have been examined in terms of the progression , metastasis , clinical efficacy , and prognosis of various cancers ; however , little is known about their effects on clinical outcome in patients with drug3 ( ESCC ) . 
drug1 genotype is predictive of clinical response after treatment with definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell drug2 . 
Overall , TNF-a drug1 polymorphism was significantly associated with the increased risk of drug2 under four genetic comparison models 
Remarkably , drug1 was a protective factor to drug2 when compared with BPH ( OR=0.550 ; 95 % CI=0.311-0.975 ) , although the statistically significant difference was lost after correction for multiple comparisons . 
No significant associations of drug1 variant were observed with drug2 , drug3 or drug4 clinicopathologic status . 
We have determined 4 frequent nonsynonymous gene polymorphisms of CYP1B1 in the human tumor cell lines panels of the National CancerInstitute ( NCI ) and the Japanese Foundation for drug5 Research ( JFCR ) : drug1 ( R48G ) , drug2 ( A119S ) , drug3 ( L432V ) , and drug4 ( N453S ) 
Seven polymorphic variants in genes drug1 , drug2 , drug3 , drug4 , drug5 , drug6 and drug7 were associated with drug8 . 
Noteworthy , the considerable number of patients carrying drug1 and drug2 alleles underlies the importance of considering pharmacogenetic testing before starting drug therapy protocols to prevent toxicity and/or lack of effectiveness in drug3 or drug4 virus infections . 
Logistic regression analysis identified two variants associated with drug3 , the 32-bp deletion within drug1 and the drug2 within the MTHFR gene . 
Univariate analysis detected one significant single-nucleotide polymorphism ( p = 0.03 ) , drug1 , within the methylenetetrahydrofolate reductase ( MTHFR ) gene associated with drug2 . 
Logistic regression analysis identified two variants associated with drug3 , the 32-bp deletion within drug1 and the p.222A/V variant ( drug2 ) within the MTHFR gene . 
We explored the influence of interactions between polymorphisms acting upon postsynaptic receptors ( DRD2 TaqA1 drug1 and DRD4 7R ) and dopamine regulators ( COMT drug2 and DAT1 ) on the expression of drug3 and personality traits in women with drug4 . 
We observed two epistatic interactions on symptom indices : interactions ( in predicted directions ) of drug1 were seen on drug3 ( p=.023 ) , and of drug2 on drug4 ( p=.014 ) , 
STUDY PURPOSES : , Analysis of influence of allelic polymorphisms C1444T of CRP gene drug1 , G ( -174 ) A of IL6 gene drug2 , A ( -308 ) G of TNF gene drug3 , G252A of LTA gene drug4 , ( -509 ) of TGFB1 gene drug5 and delta32 ( w/d ) of CCR5 gene drug6 on development of drug7 in Russian patients with MI during two years follow-up 
Methods : A total of 51 drug12 patients and 96 unrelated controls from West region of Algeria were genotyped by direct sequencing for 11 SNPs including 2 SNPs from the IL10 promoter [c.-819T > C drug1 , c.-592A > C drug2 , 6 SNPs from the TNF-a promoter [c.-1211T > C drug3 , c.-1043C drug4 , c.-1037C > T drug5 , c.-556G > A drug6 , c.-488G > A drug7 , and c.-418G > A drug8 ] , and 3 SNPs from the IL23R-IL12RB2 region [g.67747415A > C drug9 , g.67740092G > A drug10 , and g.67760140T > C drug11 ] . 
RESULTS : VARIOUS SNPS REACHED NOMINAL SIGNIFICANCE : drug12 and drug13 with drug1 and drug2 , drug14 with drug3 , drug15 with drug4 , drug16 with drug5 and drug6 , drug17 with drug7 , drug18 with drug8 , drug19 with drug9 , drug10 and drug11 . 
We found a significant genotype effect ( all P<0.017 ) for the following smoking-related phenotypes : ( i ) cigarettes smoked per day and CYP2A13 * 3 ; ( ii ) pack years smoked and CYP2A6 * 2 , CYP2A6 * 1 * 2 , drug1 , CYP2B6 * 4 and DRD2-ANKK1 2137G>A ( Taq1A ) ; ( iii ) drug3 ( assessed with the Fagestrom test ) and drug2 . 
The best-studied functional genetic variant relevant to drug2 treatment is drug1 , a single-nucleotide polymorphism in exon 1 of the OPRM1 gene that encodes the u-opioid receptor . 
METHODS : The association between the OPRM1 A118G ( Asn40Asp , drug1 ) polymorphism and drug2 and alcohol consumption was analyzed using three different population-based samples : ( a ) a Finnish cohort study , Health 2000 , with 503 participants having a DSM-IV diagnosis for drug3 and/or drug4 and 506 age- and sex-matched controls ; ( b ) a Finnish cohort study , FINRISK ( n = 2360 ) and ( c ) the Helsinki Birth Cohort Study ( n = 1384 ) . 
In the case-control study that included 187patients with drug2 ( cases ) and 189 normal subjects ( controls ) , the AA genotype and variant Met allele frequencies of drug1 in the COMTgene were significantly higher in patients with drug3 than those in the control group ( both p <0.05 ) . 
Compared with nonsmokers , European-American COMT drug1 double-variant carriers who smoked had increased odds of drug2 [adjusted odds ratio ( AOR ) 6.15 , 95 % confidence interval ( CI ) 1.32-28.78 ) ] ; 
European-American COMT drug1 double-variant carriers who smoked heavily had more frequent moderate or severe drug2 than nonsmokers ( AOR 13.7 , 95 % CI 1.2-154.9 ) . 
European-American drug1 double-variant carriers who smoked described more frequent moderate or severe drug2 than nonsmoking ( AOR 20.6 , 95 % CI 1.64-257.93 ) and never-smoking ( AOR 20.59 , 95 % CI 1.39-304.68 ) carriers , respectively . 
African-American single-variant drug1 carriers who smoked were more likely to report drug2 than the nonsmoking carriers ( AOR 6.16 , 95 % CI 1.11-33.91 ) . 
This study aimed to test the association between the Val158Met polymorphism drug1 of the catechol-O-methyl transferase gene andanorexia nervosa drug2 . 
The present association studies found no association between drug2 and drug1 when testing the allelic contrast [Utrecht odds ratio ( OR ) =1.14 , P=0.14 ; Leiden OR=1.02 , P=0.85 ] . 
Meta-analytically combined evidence from the present genotypings and the literature search shows that the effect sizes are homogeneous across studies and that drug1 is not associated with drug2 . 
the COMT drug1 SNP that reduces enzyme activity , has previously been linked to drug2 . 
Although the drug1 SNP was not a risk factor for drug2 , 
We conclude that the functional COMT drug1 SNP contributes to drug2 , drug3 and drug4 . 
The authors examined relations between reproductive factors and 5 estrogen pathway gene polymorphisms ( drug1 , drug2 , drug3 , drug4 , and COMT drug5 ) among 702 Singapore Chinese female drug6 cases and 1,578 hospital controls , of whom 433 cases ( 61.7 % ) and 1,375 controls ( 87.1 % ) were never smokers . 
The COMT drug1 A allele was positively associated with drug2 in never smokers ( for G/A or A/A vs. G/G , OR = 1.46 , 95 % CI : 1.12 , 1.90 ) but not in ever smokers . 
Thus , we hypothesized that ( 1 ) the COMT gene contributes to drug2 and ( 2 ) a COMT polymorphism ( drug1 : Val158Met ) causing thermolability of enzymatic activity affects liver enzymes ( e.g. , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) and gamma-glutamyl transpeptidase ( Î³-GT ) ) in serum . 
Recently we identified two SNPs in COMT ( drug1 and drug2 ) that are associated with drug3 in an Australian cohort . 
Individuals with drug3 were more than twice as likely to carry the GG genotype compared to the AA genotype for both the drug1 and drug2 SNPs . 
Association of both drug1 and drug2 withsubstance dependence , a common comorbidity of drug3 has not been investigated . 
The drug1 SNP was associated with drug2 . 
The drug1 SNP showed a weak association with drug2 at the allele level that did not reach significance at the genotype level but it was not associated with drug3 . 
Analysis of drug1 haplotypes also revealed association with drug2 with the G/Ghaplotype being almost 1.5 times more common in drug3 cases . 
It is possible that the drug1 SNP , in combination with drug2 , results in a common molecular variant of COMT that contributes to drug3 and drug4 susceptibility . 
However , when this relation was assessed within strata based on estrogen-related factors , a few SNPs ( HSD17B1 ( drug1 , drug2 and drug3 ) , COMT ( drug4 ) , UGT1A1 ( drug5 ) and ESR1 ( drug6 ) seemed to be related to drug7 in the same direction of their associations with drug8 . 
we examined variations in maternal and fetal COMT genes and their association with drug5 ( term vs preterm pregnancies ) using 4 functional SNPs : drug1 , drug2 , drug3 , and drug4 in both AA and Cau . 
In conclusion , our study demonstrated that a synonymous polymorphism , drug1 in the fetal COMT gene , is associated with drug2 in AA . 
Variants of drug1 drug2 and drug3 were not associated with the risk of developing drug4 . 
A common C-G-C-C-G-A haplotype for drug1 - drug2 - drug3 - drug4 - drug5 - drug6 showed an inverse association with drug7 risk in Hispanic Caucasians ( OR = 0.19 , P = 0.04 , 95 % CI = 0.04-0.95 ) and with aggressive disease status ( i.e. Gleason score >or=7 ) in non-Hispanic Caucasian cases ( OR = 0.64 , P = 0.008 , 95 % CI = 0.47-0.89 ) . 
A subset of 82 patients also underwent drug8 testing , Patients were genotyped for the MTHFR 677C>T drug1 drug2 , MTR 2756A>G drug3 MTRR 203A>G drug4 , FOLH1 484T>C drug5 , RFC 80A>G drug6 and COMT675G>A drug7 polymorphisms . 
A common Val->Met polymorphism ( drug1 ) in the COMT gene , associated with increased prefrontal dopamine catabolism , impairs prefrontal cognition and might increase risk for drug2 . 
We have previously found an association with drug1 and drug2 addiction . 
Our results suggest that individual susceptibility to drug4 incidence may be increased by combined effects of the high-risk genotypes in drug1 , drug2 , and drug3 estrogen metabolic genes . 
The Val108/158Met drug1 single nucleotide polymorphism ( SNP ) in the catechol-O-methyltransferase ( COMT ) gene contributes to genetic susceptibility to drug2 , which is specifically related to impairments in executive functioning . 
A different genomic region composed of three SNPs ( drug1 , drug2 , drug3 ) within the COMT gene has been reported to be significantly associated with drug4 in Ashkenazi Jews . 
The SNP drug1 , which has been mapped to the 3'-UTR region of the COMT gene , was significantly associated with drug2 in our family study , and possibly associated with the age of onset , delusion/hallucination symptom dimension , and CPT performance . 
Therefore , COMT may contribute to the genetic risk for drug2 not through the drug1 polymorphism , but through other variants that are situated 3 ' to this region , in the Taiwanese population . 
OBJECTIVE : The T allele of a functional polymorphism ( drug1 : LCT-13910 C>T ) , close to the lactase gene , correlates with drug2 ( LP ) in adults . 
Our aim was to test in this study , the association of drug1 with BMI and related drug2 , in interaction with dairy product consumption . 
drug2 ( PLI ) was defined as the C/C genotype of the drug1 polymorphism . 
We hypothesized that individuals with the drug2 allele of the LCT SNP ( drug1 ) would exhibit a greater degree of drug3 and that this relationship would be mediated by lactose consumption . 
The C/T-13910 lactasevariant ( drug1 ) was genotyped in 630 men with drug2 and 873 matched control participants . 
The -13910C>T polymorphism ( drug1 ) upstream from the lactase ( LCT ) gene , strongly associated with drug2 ( LP ) in Europeans , is emerging as a new candidate for drug3 . 
In contrast , haplotypes at another block tagged by drug1 associated with prevalent drug2 ( b=0.239 , p= 2.05 * 10 ( -4 ) ) , but remarkably these are inversely associated with disease severity ( b=-0.196 , p=0.003 ) . 
The presence of four common oxytocin receptor gene polymorphisms ( drug1 , drug2 , drug3 and drug4 ) was evaluated in one hundred women with drug5 and one hundred healthy women using restriction fragment length polymorphism genotyping . 
In haplotype analysis , the haplotype combination of drug1 A allele , drug2 C allele and drug3 G allele was found to be significantly associated with an increased risk of drug4 ( OR=3.2 [CI 1.04-9.8 ] , p=0.043 ) . 
With respect to OXTR drug1 , mothers with the GG genotype showed greater drug2 across varying levels of interparental conflict . 
The aim of this study was to investigate whether a set of single nucleotide polymorphisms ( SNPs ) within cyclooxygenase-2 ( COX-2 , drug1 and drug2 ) and oxytocin receptor ( OXTR , drug3 and drug4 ) genes was associated with drug5 , response or remission . 
For this purpose , two single nucleotide polymorphisms ( SNPs ) , 6930G>A ( drug1 ) and 9073G>A ( drug2 ) , within the oxytocin receptor gene ( OXTR ) , were studied in a cohort of 185 patients with major drug3 ( 50.3 % ) or drug4 I or II disorders ( 49.7 % ) and 192 matched healthy controls . 
A positive association between the GG genotype of drug1 SNPs ( 6930G>A or 9073G>A ) and unipolar drug2 was demonstrated . 
For drug1 , overtransmission of the G allele to probands with drug2 disorder was found which contrasts with the overtransmission of A previously reported in the Chinese Han sample . 
RESULTS : The family-based association test ( FBAT ) revealed a significant genetic association between drug3 and two of the SNPs tested ( drug1 A : Z = 2.287 , p = .0222 ; drug2 A : Z = 2.573 , p = .0101 ) . 
When haplotypes were constructed with two , three , and four markers , the haplotype-specific FBAT revealed that a number of haplotypes , particularly those involving drug1 , were significantly associated with drug2 . 
CONCLUSIONS : Our meta-analysis suggests that the G allele of drug1 polymorphism might be a potential risk factor for drug2 , especially in whitepopulations . 
The real-time polymerase chain reaction ( RT-PCR ) was used to analyze 4 SNPs ( drug1 A/G , drug2 A/G , drug3 A/G , drug4 C/G ) in 291 drug5 patients and 247 controls . 
Analysis of 4 SNPs revealed a significant difference in the genotype distribution for drug1 , drug2 , and drug3 between drug5 patients and controls ( p = 0.041 , p = 0.005 , p = 0.023 , respectively ) but not for drug4 ( p = 0.211 ) . 
Minor alleles in three correlated ht SNPs ( drug1 , , drug2 , and drug3 ; r ( 2 ) >0.6 ) were associated with increased risk for drug4 . 
